2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, jco2400767. PMID: 39255440, DOI: 10.1200/jco.24.00767.Peer-Reviewed Original ResearchAdvanced papillary renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaOverall survivalCell carcinomaProlonged progression-free survivalLack of survival benefitProgression-free survivalRandomized phase IIMedian follow-upPrimary end pointOpen-label trialOverall survival analysisCrizotinib armMedian OSSurvival benefitClinical trial updateNo significant differenceCabozantinibTreatment armsSunitinibFollow-upClinical trialsSavolitinibCrizotinibTIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaRenal cell carcinoma tumorsT cellsTIGIT expressionCheckpoint inhibitorsPD-1Likelihood of response to therapyTumor-infiltrating T cellsCD3+ T cellsRenal cell carcinoma metastasisTreatment of renal cell carcinomaImmune checkpoint inhibitorsInfiltrating T cellsPurposeImmune checkpoint inhibitorsResponse to therapyT cell immunoglobulinCD3+ levelsMetastatic RCC specimensAdjacent normal renal tissuesNormal renal tissuesQuantitative immunofluorescence analysisCell carcinomaResistant diseasePotential therapeutic targetTissue microarrayPathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma
Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Lerner S, Pal S, Shuch B. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International 2024, 134: 596-601. PMID: 39014969, DOI: 10.1111/bju.16403.Peer-Reviewed Original ResearchPapillary renal cell carcinomaPositive predictive valueRenal cell carcinomaLocal pathology reviewCentral reviewPathology reviewCell carcinomaAdvanced papillary renal cell carcinomaMetastatic papillary renal cell carcinomaPapillary renal cell carcinoma subtypesPatients treated with targeted therapyExpert genitourinary pathologistsPathological concordance rateLocal reviewGenitourinary pathologistsClinical benefitCabozantinibClinical significanceClinical valueSubtype assignmentConcordance rateType 1CarcinomaPatientsPredictive valueSarcomatoid and Rhabdoid Renal Cell Carcinoma
Adeniran A, Shuch B, Humphrey P. Sarcomatoid and Rhabdoid Renal Cell Carcinoma. The American Journal Of Surgical Pathology 2024, 48: e65-e88. PMID: 38736105, DOI: 10.1097/pas.0000000000002233.Peer-Reviewed Original ResearchRenal cell carcinomaSarcomatoid renal cell carcinomaGenomic alterationsRhabdoid differentiationRhabdoid cellsCell carcinomaWHO classification of renal tumorsClassification of renal tumorsInternational Collaboration on Cancer ReportingHistologic types of renal cell carcinomaPleomorphic undifferentiated sarcomaMalignant spindle cellsAggressive biological behaviorMolecular featuresMolecular mechanisms of tumorigenesisMechanisms of tumorigenesisSarcomatoid growthRhabdoid componentSarcomatoid componentRhabdoid featuresRenal tumorsClinical responseCollege of American PathologistsRhabdoid morphologySarcomatoid elements
2023
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaBrain metastasesPrimary tumorTumor microenvironmentDigital spatial profilingCell carcinomaActivation protein expressionInflammatory macrophage markersRCC brain metastasesInnate immune activatorsNormal kidney samplesProgressive stagesExtracranial metastasesTim-3Immune checkpointsImmune dysfunctionImmune activationRCC metastasisLonger survivalImmune activatorsMacrophage markersTreatment responseSeparate cohortTissue microarrayMetastatic samples
2016
Racial disparities in renal cell carcinoma: a single‐payer healthcare experience
Mafolasire A, Yao X, Nawaf C, Suarez‐Sarmiento A, Chow W, Zhao W, Corley D, Hofmann JN, Purdue M, Adeniran AJ, Shuch B. Racial disparities in renal cell carcinoma: a single‐payer healthcare experience. Cancer Medicine 2016, 5: 2101-2108. PMID: 27228559, PMCID: PMC4884637, DOI: 10.1002/cam4.755.Peer-Reviewed Original ResearchConceptsDisease-specific survivalRenal cell carcinomaBlack patientsIndependent predictorsSurgical treatmentWhite patientsCell carcinomaRacial disparitiesKaiser Permanente Northern California systemWorse disease-specific survivalCox proportion hazard modelAdvanced American Joint CommitteePapillary renal cell carcinomaKaplan-Meier methodProportion hazard modelAmerican Joint CommitteeLarger tumor sizeCase-control studyHealthcare systemSingle-payer healthcare systemSingle healthcare systemSignificant racial disparitiesOverall survivalPatient demographicsDifferent comorbiditiesGenomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 2170-2175. PMID: 26864202, PMCID: PMC4776463, DOI: 10.1073/pnas.1525735113.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellCell DedifferentiationDNA Mismatch RepairDNA-Binding ProteinsExomeFemaleGenes, p53HumansKidney NeoplasmsLoss of HeterozygosityMaleMiddle AgedMutationNuclear ProteinsOncogenesPolymorphism, Single NucleotidePrognosisTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseConceptsClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaSarcomatoid elementsCarcinomatous elementsCell carcinomaSomatic single nucleotide variantsVon Hippel-Lindau tumor suppressorPoor-prognosis cancerTreatment of patientsTumor protein p53 (TP53) mutationsMismatch repair deficiencyRich interaction domain 1ASarcomatoid featuresPoor prognosisUnknown pathogenesisPolybromo-1TP53 mutationsP53 mutationsSarcomatoid transformationPan-cancer genesExome sequencingTumorsRepair deficiencyProtein 1The incidence of adverse pathologic characteristics in small renal masses as size increases.
Nawaf C, Rosoff J, Adeniran A, Humphrey P, Shuch B. The incidence of adverse pathologic characteristics in small renal masses as size increases. Journal Of Clinical Oncology 2016, 34: 596-596. DOI: 10.1200/jco.2016.34.2_suppl.596.Peer-Reviewed Original ResearchAdverse pathologic featuresRenal cell carcinomaActive surveillanceLymphovascular invasionPathologic featuresRenal massesAdverse pathologic characteristicsCT1a renal massesHistologic tumor necrosisRenal tumor biopsySelection of patientsSingle-institution databaseType II histologyHigh nuclear gradeTumor size categoriesSmall renal massesSignificant increaseSarcomatoid featuresPathologic characteristicsTumor sizeCell carcinomaPrimary tumorAUA guidelinesHistologic characteristicsLarge tumors